RxDoctor Payments Data

Kathleen Spadoni

Family · Worcester, MANPI 1649641689

Payments from drug & device makers

$1,162in general payments, 2019–2025

Across 48 payments — averaging $24.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$336
  • AstraZeneca$329
  • Nestle Healthcare Nutrition Inc.$91
  • Johnson & Johnson$62
  • Esperion Therapeutics, Inc.$55
  • Biogen$46
  • plus $244 from 10 others

What the payments were for

  • Food & beverage$1,162100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,162 in reported general payments places this provider in the 80th percentile of 2,320 family providers in Massachusetts.

See all family providers in Massachusetts

Medicare billing

Part B allowed, 2024
$132,541
Medicare patients
189
Services billed
1,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide53$37,373
EliquisApixaban83$25,106
MyrbetriqMirabegron56$12,875
ArexvyRsvpref3 Antigen/As01e/Pf24$7,186
JardianceEmpagliflozin14$4,181
Pantoprazole Sodium71$3,097
Esomeprazole Magnesium18$2,138
Mirabegron ErMirabegron19$1,822
Divalproex Sodium27$1,808
Mirtazapine61$1,632
Tresiba Flextouch U-100Insulin Degludec13$1,525
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$1,457
Fentanyl20$1,326
LantusInsulin Glargine,hum.Rec.Anlog17$1,258
Oxycodone Hcl146$1,249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$25,10683 claims
GSKArexvy$28$7,18624 claims
Boehringer IngelheimJardiance$21$4,18114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,320 family providers in Massachusetts.

Other family in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →